A clinical briefing on Airsupra availability in 2026 for prescribers. Covers supply status, insurance landscape, patient access barriers, and alternative strategies.
Airsupra (albuterol 90 mcg/budesonide 80 mcg per actuation) has brought a meaningful shift to asthma rescue therapy since its FDA approval in January 2023. As the first and only rescue inhaler combining a short-acting beta2-agonist with an inhaled corticosteroid, it offers patients both immediate bronchodilation and anti-inflammatory benefit with each use — aligning with GINA recommendations for ICS-containing reliever therapy.
However, patient access to Airsupra continues to present challenges in 2026. This briefing provides an overview of the current supply landscape, prescribing considerations, and resources to help your patients get their prescriptions filled.
Airsupra has not been subject to a formal FDA or ASHP drug shortage at any point since its approval. AstraZeneca has maintained production without reported manufacturing disruptions.
That said, the practical reality for patients is more complicated:
When considering Airsupra for your patients, several practical factors warrant attention:
Airsupra is approved for adults 18 and older. It's indicated as a rescue inhaler for as-needed use — the typical dose is 2 inhalations, with a maximum of 12 inhalations (6 doses) per 24 hours. It is not approved for pediatric patients, and it is not a maintenance inhaler.
Ideal candidates include patients who:
For a detailed pharmacology overview, see our article on Airsupra's mechanism of action.
The gap between Airsupra being "available" and patients being able to fill their prescriptions is real. The core barriers are:
Understanding the financial picture helps set patient expectations:
Note: The SUPRA Savings Card is not valid for government-insured patients (Medicare, Medicaid, VA, TRICARE). For these patients, the AZ&Me program may provide assistance.
Several resources can help your practice manage Airsupra access challenges:
Medfinder allows providers and staff to check real-time pharmacy stock for Airsupra and direct patients to pharmacies that have it available. This can significantly reduce the back-and-forth of phone calls and pharmacy transfers.
AstraZeneca offers PA support resources through their healthcare provider portal. Having clinical documentation ready — specifically documenting that the patient has asthma requiring rescue therapy and the rationale for a SABA/ICS combination — can expedite the process.
Patients who understand what Airsupra is and why it may be harder to find are better equipped to navigate the process. Consider directing them to:
Several trends suggest Airsupra access will continue to improve through 2026 and beyond:
However, no generic version of Airsupra is on the horizon for 2026, meaning cost and access barriers will persist for the foreseeable future.
Airsupra represents an important advance in asthma rescue therapy, but prescribing it effectively in 2026 requires awareness of the access landscape. Proactive strategies — using Medfinder for providers, connecting patients with savings programs, and preparing for prior authorization — can make the difference between a prescription that gets filled and one that doesn't.
For alternative prescribing strategies when patients can't access Airsupra, see our provider's guide to helping patients find Airsupra or review the alternatives to Airsupra.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
